ArticleNature reviews. Immunology2017
Immunosuppressive cell death in cancer.
Article in Nature reviews. Immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Sequential nanocatalytic therapy and lysosomal dysfunction for overcoming castration-resistant prostate cancer.Bioactive materials · 2026Article
- Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming.Journal of hematology & oncology · 2026Review
- Plasma IFN-γ may predict pyrotinib efficacy in patients with HER2-positive advanced breast cancer.Biomedical reports · 2025Article
- Complete response of gallbladder cancer treated with gemcitabine and cisplatin chemotherapy combined with durvalumab: A case report and review of literature.World journal of gastrointestinal oncology · 2025Article
- Review
- EPA, DHA, and resolvin effects on cancer risk: The underexplored mechanisms.Prostaglandins & other lipid mediators · 2024Review
- Article
- Tumor cell-derived spermidine is an oncometabolite that suppresses TCR clustering for intratumoral CD8Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Regulation of immunological tolerance by the p53-inhibitor iASPP.Cell death & disease · 2023Article
- Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression.Science translational medicine · 2022Article
- Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations.Nature communications · 2022Article
- Dying tumor cell-derived exosomal miR-194-5p potentiates survival and repopulation of tumor repopulating cells upon radiotherapy in pancreatic cancer.Molecular cancer · 2020Article
- Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy.Nanomedicine (London, England) · 2020Article
- Review
- Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).International journal of oncology · 2018Review
Corrections and comments
- Commented on by
- Comment on
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.